Rheumatology Department, Cochin Hospital
Paris, IDF, 75014, France
Location status: Recruiting
NCT Number: NCT05534347
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Interested in participating?
Request Info16 year and older
All sexes
Observational
Paris, IDF, 75014, France
Location status: Recruiting
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.
The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Addtional tube of blood needed for follow up of patients
Joint puncture if needed according to routine care of the patients
Time frame: 5 years
Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.
Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.
Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.
Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.
Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Severity of JIA
Time frame: 5 years
Severity of JIA
Time frame: 5 years
Structural damage determined by x-rays during follow up.
Time frame: At inclusion
Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.
Time frame: At inclusion
Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA.
Contact information is provided by the study sponsor or research team.
Marie BENHAMMANI-GODARD
CONTACT
Yannick ALLANORE, PD, PhD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Acronym: MAJIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07087912
Ankylosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
São Paulo, Brazil
View Trial DetailsNCT07602595
Arthritis, Arthritis, Juvenile
Cincinnati, Ohio, United States
View Trial DetailsNCT07553182
Arthritis, Arthritis, Juvenile
Le Kremlin-Bicêtre, France
View Trial DetailsNCT07234747
Arthritis, Arthritis, Juvenile
Istanbul, Buyukcekmece, Turkey (Türkiye)
View Trial Details